文献速递重症综合管理与镇静镇痛

高影响力重症医学随机对照试验中的复合结局指标:一项系统评价

Composite outcome measures in high-impact critical care randomised controlled trials: a systematic review.
PubMed 文献 · Crit Care · 2024-05-28
一句话结论重症RCT中复合结局使用率升至39.1%,但其效应估计在各组分间常不一致,且93%含非患者重要组分,影响结局解读。

该系统评价筛选16本高影响力期刊2012至2022年发表的8271项随机对照试验,纳入194项涉及重症患者并报告患者重要结局的试验。结果显示39.1%的试验使用复合结局指标且随时间增加,但仅52.6%明确描述为复合结局,中位组分数为2(IQR 2-3)。使用复合结局的试验招募参与者更少(409(198.8-851.5) vs 584(300-1566),p=0.004),且与统计学显著性率增加无关(19.7% vs 17.8%,p=0.380)。除6项试验外,所有试验的预测效应量均被高估;仅43.4%的试验效应估计在所有组分间一致,93%的复合结局包含非患者重要组分。

要点

  • 高影响力重症RCT中39.1%使用复合结局指标,且使用率随时间增加,但仅52.6%明确描述为复合结局。
  • 使用复合结局的试验招募参与者更少(409(198.8-851.5) vs 584(300-1566),p=0.004),与统计学显著性率增加无关(19.7% vs 17.8%,p=0.380)。
  • 仅43.4%的使用复合结局的试验效应估计在所有组分间一致,效应估计不一致会混淆结局解读。
  • 93%的复合结局包含非患者重要组分,中位组分数为2(IQR 2-3)。
  • 除6项试验外,所有试验的预测效应量均被高估。

适用人群与场景

  • 2012至2022年发表于16本高影响力期刊、报告患者重要结局并涉及重症患者的随机对照试验,共纳入194项。

研究设计与关键结果

  • 系统评价筛选8271项试验,纳入194项;39.1%的试验使用复合结局指标,且使用率随时间增加。
  • 使用复合结局的试验中仅52.6%明确描述为复合结局;复合结局中位组分数为2(IQR 2-3)。
  • 使用复合结局的试验招募参与者更少(409(198.8-851.5) vs 584(300-1566),p=0.004),其使用与统计学显著性率增加无关(19.7% vs 17.8%,p=0.380)。
  • 除6项试验外,所有试验的预测效应量均被高估;使用复合结局的试验中43.4%的效应估计在所有组分间一致。
  • 93%的复合结局包含非患者重要组分。

证据类型、等级与局限

  • 证据类型:系统评价,纳入16本高影响力期刊的194项随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The use of composite outcome measures (COM) in clinical trials is increasing. Whilst their use is associated with benefits, several limitations have been highlighted and there is limited literature exploring their use within critical care. The primary aim of this study was to evaluate the use of COM in high-impact critical care trials, and compare study parameters (including sample size, statistical significance, and consistency of effect estimates) in trials using composite versus non-composite outcomes.

METHODS: A systematic review of 16 high-impact journals was conducted. Randomised controlled trials published between 2012 and 2022 reporting a patient important outcome and involving critical care patients, were included.

RESULTS: 8271 trials were screened, and 194 included. 39.1% of all trials used a COM and this increased over time. Of those using a COM, only 52.6% explicitly described the outcome as composite. The median number of components was 2 (IQR 2-3). Trials using a COM recruited fewer participants (409 (198.8-851.5) vs 584 (300-1566, p = 0.004), and their use was not associated with increased rates of statistical significance (19.7% vs 17.8%, p = 0.380). Predicted effect sizes were overestimated in all but 6 trials. For studies using a COM the effect estimates were consistent across all components in 43.4% of trials. 93% of COM included components that were not patient important.

CONCLUSIONS: COM are increasingly used in critical care trials; however effect estimates are frequently inconsistent across COM components confounding outcome interpretations. The use of COM was associated with smaller sample sizes, and no increased likelihood of statistically significant results. Many of the limitations inherent to the use of COM are relevant to critical care research.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Walker HGM, Brown AJ, Vaz IP, et al. Composite outcome measures in high-impact critical care randomised controlled trials: a systematic review. Crit Care. 2024. PMID: 38807143. doi:10.1186/s13054-024-04967-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。